Leroy Xavier, Buisine Marie-Pierre, Leteurtre Emmanuelle, Aubert Sebastien, Buob David, Porchet Nicole, Copin Marie-Christine
Service d'Anatomie Pathologique, Pôle Eurasanté, Bâtiment Biologie-Pathologie, CHRU, 59037 Lille.
Ann Pathol. 2006 Sep;26(4):257-66. doi: 10.1016/s0242-6498(06)70718-0.
MUC1 is a large trans-membrane highly glycosylated mucin which is expressed at the apical pole of normal cells in glandular epithelia. MUC1 is implicated in many physiological mechanisms such as adhesion, development and differentiation. Also, MUC1 is frequently deregulated and over-expressed with a membrane circumferential and/or cytoplasmic expression. The intracellular tail of MUC1 is phosphorylated and can interact with many signalling proteins and transcriptional factors. Indeed, MUC1 can interact with B-catenin competitively for E-cadherin, thus destabilizing intercellular junctions and favouring metastatic dissemination. In carcinomas, the overexpression and membrane delocalization of MUC1 is associated with a worse prognosis and a shorter survival in breast, colon, kidney, prostate or gastro-intestinal cancers. MUC1 appears to be a novel therapeutic target for immunotherapy or anti-tumour vaccines.
MUC1是一种大型跨膜高度糖基化粘蛋白,在腺上皮正常细胞的顶端表达。MUC1参与许多生理机制,如黏附、发育和分化。此外,MUC1经常失调并过度表达,呈现膜周向和/或细胞质表达。MUC1的细胞内尾部被磷酸化,可与许多信号蛋白和转录因子相互作用。事实上,MUC1可与β-连环蛋白竞争性结合E-钙黏蛋白,从而破坏细胞间连接并促进转移扩散。在癌症中,MUC1的过表达和膜定位异常与乳腺癌、结肠癌、肾癌、前列腺癌或胃肠道癌的预后较差和生存期较短相关。MUC1似乎是免疫疗法或抗肿瘤疫苗的一个新的治疗靶点。